Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups
|
01 September 2020 |
Phase I clinical trial initiated for monoclonal antibody combination for the prevention and treatment of COVID-19
|
25 August 2020 |
AstraZeneca concludes agreement with the European Commission for the supply of up to 400 million doses of AZD1222 COVID-19 vaccine
|
14 August 2020 |
COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial
|
20 July 2020 |
AstraZeneca to supply Europe with up to 400 million doses of Oxford University's vaccine at no profit
|
13 June 2020 |
AstraZeneca takes next steps towards broad and equitable access to Oxford University's COVID-19 vaccine
|
05 June 2020 |
Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients
|
05 June 2020 |
AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford's potential new vaccine
|
22 May 2020 |
AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine
|
30 April 2020 |
AstraZeneca and Saint Luke’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients
|
23 April 2020 |